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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: To retrospectively analyze the clinical manifestations of Mycoplasma
pneumoniae (M. pneumoniae)-associated encephalopathy in pediatric patients.
Methods: Pediatric patients with positive serum anti-M. pneumoniae immunoglobulin M (IgM)
were enrolled in this study. Clinical signs and symptoms, laboratory data, neuroimaging find-
ings, and electrophysiological data were reviewed.
Results: Of 1000 patients identified, 11 (1.1%; male:female ratio Z 7:4) had encephalopathy
and were admitted to the pediatric intensive care unit. Clinical presentation included fever,
symptoms of respiratory illness, and gastrointestinal upset. Neurological symptoms included
altered consciousness, seizures, coma, focal neurological signs, and personality change. Neu-
roimaging and electroencephalographic findings were non-specific. Specimens of cerebrospinal
fluid (CSF) for M. pneumoniae polymerase chain reaction (PCR) were negative. Higher M. pneu-
moniae IgM titers and longer intervals between respiratory and CNS manifestations were asso-
ciated with worse outcomes.of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Number 325, Chenggong
iwan, ROC.
ahoo.com.tw (H.-C. Fan).
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498 C.-F. Hu et al.Conclusion: Clinical manifestations of M. pneumoniae-associated encephalopathy were vari-
able. Diagnosis of M. pneumoniae encephalopathy should not rely on CSF detection of M. pneu-
moniae by PCR. M. pneumoniae IgM titers and intervals between respiratory and CNS
manifestations might be possibly related to the prognosis of patients with M. pneumoniae-
associated encephalopathy.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Encephalitis refers to an acute, usually diffuse, inflamma-
tory process affecting the brain.1 The incidence is approx-
imately 1.5e13.8 cases per 100,000.2,3 Encephalitis can be
caused by a variety of afflictions, most often by a virus, but
occasionally by bacteria or other pathogens. Encephalopa-
thy is a brain disease, damage, or malfunction. The causes
of encephalopathy are numerous and varied. The majority
of cases arise from infection, liver damage, anoxia, or
kidney failure. Whether known or unknown infections cause
encephalitis, leading to infection-associated encephalopa-
thy, remains unclear.4
A series of microbes can cause acute encephalopathy,
but agents, in most cases, remain unknown. Mycoplasma
pneumoniae is a common pathogen of the respiratory sys-
tem in school-aged children and young adults.5 The preva-
lence of M. pneumoniae was 10% in 2010, 17% in 2011, and
15% in 2012, supporting a trend of cyclic endemics every
3w5 years for M. pneumoniae infections in Taiwan.6 This
microorganism can affect blood, skin, joints, central ner-
vous system (CNS), liver, pancreas, and the cardiovascular
system, causing extrapulmonary manifestations.7,8 M.
pneumoniae-associated neurologic illness is not rare and is
identified in 1% of encephalopathy cases.9 Over the years,
several case reports have described a wide variety of
complications associated with M. pneumoniae infection,
including cases with neurologic complications in the
absence of systemic symptoms and cases that appear to be
post-infectious, rather than being caused directly by the
organism.10,11 Despite several cases being reported for
many years, the extent to which M. pneumoniae is involved
in the causation of human neurologic disease is not yet
known.
Several laboratory methods can detect M. pneumoniae
infection, including isolation, complement fixation,
serology, and molecular assays. However, each of these
methods has limitations. Isolation of M. pneumoniae is
inconvenient, time-consuming, and causes the generation
of inconsistent results.12 Although direct detection of M.
pneumoniae from brain tissue and/or cerebrospinal fluid
(CSF) supports the belief that M. pneumoniae is a major
cause of encephalopathy, the positive rate of detection of
M. pneumoniae from CSF specimens by polymerase chain
reaction (PCR) is variable and low.13 Commercially avail-
able serologic test kits for the detection of antibodies to M.
pneumoniae, possess inherent limitations of specificity and
sensitivity. The test relies on patient compliance with the
timely acquisition of acute- and convalescent-phase serum
samples for accurate interpretation. However, the serologytesting for the diagnosis of M. pneumoniae is imprecise,
because patients with neurologic involvement due to other
agents may sometimes develop elevated antibody titers to
M. pneumoniae.5 Despite these drawbacks, serology is still
a sensitive test for detecting acute M. pneumoniae infec-
tion in pediatric patients in contrast with adult patients.8
Furthermore, several papers continue to suggest that the
immunoglobulin M (IgM) test is a readily convenient method
to assist in the diagnosis of M. pneumoniae-associated
encephalopathy.8,10e12
Neurological sequelae in M. pneumoniae-associated CNS
illness are very high. A mounting number of reports show
neurological sequelae in 48e64% of cases of M. pneumo-
niae-associated encephalopathy.14 Despite the fact that
therapies including antibiotics, intravenous immunoglobulin
(IVIG), and steroids have been proposed by several articles,
the role of these treatments in M. pneumoniae-associated
encephalopathy remains unclear, because the benefits of
these treatments lack the comparison of control groups in
clinical trials and spontaneous recovery in some cases
without any treatment has been reported.5,8,14 Therefore,
because there is no strong evidence to support these
treatments, it is worth exploring the related prognostic
factors for M. pneumoniae-associated encephalopathy.
Narita et al15 reported that “intervals between respira-
tory and CNS manifestations” may be pivotal in under-
standing the mechanism of M. pneumoniae-associated
encephalopathy. They proposed that if the interval is <7
days, the mechanism for M. pneumoniae is direct invasion.
Adversely, if the intervals are >7 days, the mechanism is
immune-mediated. However, if the interval is a key point in
approaching the mechanisms of M. pneumoniae-associated
encephalopathy, a retrospective analysis of medical re-
cords may verify the connection between the mechanisms
of this disease and the intervals. Moreover, whether these
connections relate to the outcomes of patients with M.
pneumoniae-associated encephalopathy, are worthy of
further investigation. We therefore conducted a retro-
spective review of charts targeting M. pneumoniae-associ-
ated encephalopathy and analyzed their outcomes after
discharge for 6 months.Methods
Selection criteria
From January 1, 2003 to December 31, 2010 patients were
selected for inclusion in this study if they fulfilled the
following criteria: (1) <18 years of age; (2) positive for M.
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neurologic symptoms; and (3) any new-onset of acute en-
cephalopathy symptoms, including confusion, disorienta-
tion, coma, or inability to talk, new onset of seizures, focal
neurological signs (tremor, rigidity, dysarthria, acute urine
retention, decreased muscular power, or decreased deep
tendon reflex), and personality or behavioral change.
Instead, patients with a history of neurological illness,
such as meningitis, seizure/epilepsy, family history of
seizure/epilepsy, progressive neurological disorder, elec-
trolyte imbalance, or co-infection, were excluded. All in-
formation was collected by retrospective chart review
regarding age, sex, clinical symptoms, electroencephalog-
raphy, neuroimaging, and clinical laboratory tests,
including complete blood count, C-reactive protein (CRP),
and CSF analysis. This study was approved by the local
institutional review board (Tri-Service General Hospital
Institutional Review Board approval number 100-05-130).
IgM for the detection of M. pneumoniae
IgM-capture enzyme-linked immunosorbent assay (ELISA;
Sero M. pneumoniae Kit, Savyon Diagnostics Ltd., Ashdod,
Israel) were used for M. pneumoniae detection. The gener-
ated microplate-based IgM-ELISA results were considered
positive when more than 20 BU/mL of specific antibodies to
M. pneumoniae per milliliter serum were present. We
rechecked the datum 2 weeks later if the initial value was
within 10w20 BU/ml, and considered it was positive if the
result of second serum sample was more than 20 BU/ml, and
negative if the result was less than 20 BU/ml.
PCR for the detection of M. pneumoniae
CSF samples were obtained within 1e2 days following
admission, refrigerated at 4C for <72 hours, and then
frozen at e70C before PCR assay. The DNA extraction and
PCR amplification protocol were according to the method of
Lin et al.16
Other laboratory investigations
Blood and CSF samples from all these cases underwent
bacterial cultures, viral isolation, serology tests, and PCR to
identify possible pathogens such as Epstein-Barr virus
(EBV), herpes simplex virus (HSV), varicella-zoster virus
(VZV), and enterovirus, and the detection of Influenza A/B
antigen.
Outcomes
Patients’ outcomes were determined based on evaluation
records of the clinic visit 6 months or more after the en-
cephalopathy episode. For purposes of data analysis, out-
comes were divided into “good” or “poor” according to the
patients’ 6-month follow-up. A “good response” indicated
that the patient had fully recovered and all neurological
functions had returned to baseline, whereas a “poor
response” indicated that the patient still had neurological
or psychological symptoms that were not recorded before
admission.Statistical data
Statistical analysis was performed using SPSS 18.0 (SPSS,
Inc., Chicago, IL, USA). Descriptive statistics and quanti-
tative data are expressed as mean  standard deviation and
percentages. Fishers’ exact test was used in the comparison
of clinical neurological manifestations, serum IgM level,
and intervals between respiratory illness and the onset of
neurological symptoms. The prognostic values of IgM titers
and intervals were analyzed using the receiver operating
characteristic (ROC) curve and established optimal cutoffs
corresponding to the highest differential positive rate:
[sensitivity e (1 e specificity)]. Statistical significance was
set at a Z 0.05, p < 0.05.Results
Of 1000 pediatric patients (male:female ratio Z 549:451)
with positive anti-M. pneumoniae IgM, 11 children (1.1%;
male:female ratio Z 7:4) presented with encephalopathy
and were admitted to the pediatric intensive care unit.
Their ages ranged from 3 years to 17 years (meanZ 8  4.2
years). Presenting features included fever (10/11), respi-
ratory illness (11/11), gastrointestinal symptoms (3/11),
altered level of consciousness (8/11), coma (3/11), gener-
alized tonic-clonic seizures (4/11), focal neurological signs
(6/11), and personality or behavioral change (3/11; Table
1). Chest radiographs revealed perihilar infiltration
without pneumonia (11/11). The average intervals between
respiratory illness and onset of neurological symptoms were
9.2  4.5 days (range Z 1e14 days; Table 1).
The patients’ white blood cell (WBC) counts, platelet
counts, and glucose levels were within the normal range,
but serum CRP levels were mildly elevated (0.7  0.7 mg/
dL). In addition, biochemistry and cell count studies of CSF
were within the normal range, except that the WBC count
showed mild pleocytosis (28.6  71.3/mm3). The CSF PCR
for detection of M. pneumoniae was negative (Table 1).
Electroencephalography (EEG; n Z 11) revealed diffuse
slowing activity (7/11), epileptiform discharge (4/11), and
normal findings (2/11; Table 1). Cranial computed tomog-
raphy (CT) scans (nZ 7) were performed on admission, and
no leptomeningeal enhancement or brain swelling was
noted. Brain MRI (n Z 8), which was performed during
hospitalization from 2 days to 1 week, revealed a diffuse
high-intensity signal in the cortex (1/8), meningeal
enhancement (3/8), decreased N-acetyl aspartate/creatine
(NAA) ratio (2/8), unilateral ventricle dilatation (1/8), and
normal findings (2/8; Table 1).
Eight patients (72.7%) received a 3-day course of a
macrolide (azithromycin 10 mg/kg). Case 2 received
methylprednisolone and IVIG, because of rapid deteriora-
tion of neurological function. Cases 6 and 9 received azi-
thromycin and IVIG in an attempt to accelerate recovery.
Cases 1 and 4 did not receive azithromycin, corticosteroids,
or IVIG, due to a delay in diagnosis and only Case 1 recov-
ered completely without neurological sequelae.
Sequelae at 6 months or more for follow-up included
focal seizures (2/11), mental impairment (2/11), muscle
rigidity and joint contracture (1/11), and decreased muscle
power (1/11). Five patients fully recovered and six showed
Table 1 Clinical symptoms, laboratory data, brain electrophysiological profile, brain images, treatment, and outcome
Case Sex Age
(y)
Prodrome CNS
manifestation
Intervals
between
respiratory
and CNS
manifestations
(d)
Serum CSF EEG CT MRI Treatment Sequelae Outcome
at 6-mo
follow-up
WBC
(no./mL)
CRP
(mg/dL)
IgM
(BU/mL)
WBC
(no./mL)
RBC
(no./mL)
TP
(mg/dL)
Glucose
(mg/dL)
PCR
1 M 13 RI, N/V A, F 5 3930 0.40 39.90 240 0 43 61 Negative Normal Normal ND None Normal Good
2 M 7 Fever, RI A, F 11 8100 0.19 73.42 6 14 24 61 Negative MFE ND DN Methylprednisolone
IVIG
MJ Poor
3 M 5 Fever, RI A 1 17,320 2.63 10.20 3 9 14 62 Negative SW Normal ME Azithromycin Normal Good
4 M 10 Fever, RI A, P 14 4900 0.03 62.70 0 4 20 81 Negative SW ND Normal None MI Poor
5 F 4 Fever, RI, N/V A, P 4 4310 0.50 20.10 0 2 24 68 Negative SW Normal ND Azithromycin Normal Good
6 M 6 Fever, RI C, S 12 19,520 0.99 109.20 0 2 28 76 Negative MFE SW ND DS Azithromycin IVIG FS Poor
7 M 3 Fever, RI, N/V C, F, S 14 8900 0.54 87.00 0 2 20 74 Negative SW Normal ME Azithromycin DP Poor
8 M 17 Fever, RI A 10 8300 0.60 152.00 0 6 21 63 Negative SW Normal DV Azithromycin MI Poor
9 F 10 Fever, RI A, F 7 3900 0.78 21.90 0 4 14 55 Negative Normal ND Normal Azithromycin IVIG Normal Good
10 F 7 Fever, RI A, F, P, S 9 1200 0.65 26.60 30 18 69 84 Negative MFE SW Normal ME DN Azithromycin Normal Good
11 F 6 Fever, RI C, F, S 14 17,700 0.39 154.60 35 60 94 83 Negative GE Normal ND Azithromycin FS Poor
Mean  SD 8  4.2 9.2  4.5 9734.6 
5855.9
0.7 
0.7
68.9 
51.9
28.6 
71.3
11.0 
17.2
33.7 
25.5
69.8 
10.2
AZ altered consciousness; BUZ binding units; CZ coma; CRPZ C-reactive protein; CSFZ cerebrospinal fluid; CTZ computed tomography; DNZ decreased NAA peak; DPZ decreased
muscle power; DSZ high diffuse signal in cortex; DVZ dilatation of right ventricle; EEGZ electroencephalography; FZ focal neurological signs (tremor, rigidity over limbs, dysarthria,
acute urine retention, decreased muscular power, decreased deep tendon reflex); FS Z focal seizures; GE Z generalized epileptiform discharge; IgM Z immunoglobulin M;
IVIG Z intravenous immunoglobulin; ME Z meningeal enhancement; MFE Z multifocal epileptiform discharge; MI Z mental impairment; MJ Z muscle rigidity and joint contracture;
MRIZ magnetic resonance imaging; NDZ not done; N/VZ nausea or vomiting; PZ personality and behavioral change; PCRZ polymerase chain reaction for detection of Mycoplasma
pneumoniae; RBC Z red blood cell count; RI Z respiratory illness; S Z seizure; SW Z slow wave; TP Z total protein; WBC Z white blood cell count.
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clinical visit (Table 1). We evaluated the clinical neuro-
logical manifestations, serum IgM level, and intervals be-
tween respiratory illness and onset of neurological
symptoms between the good and the poor outcome groups.
We found coma (p Z 0.03), IgM level >60 BU/mL
(p Z 0.008), and intervals between respiratory illness and
onset of neurological symptoms >10 (p Z 0.008) all in the
poor outcome group (Fig. 1). The optimal cutoff calculated
in our series of patients was 9.5 days for the intervals be-
tween respiratory illness and onset of neurological symp-
toms and 51.3 BU/mL for IgM levels by the ROC curve.
Discussion
Although fever and respiratory tract symptoms were com-
mon in our cases and others,8 the clinical signs and symp-
toms caused by M. pneumoniae, including diverse
manifestations, CSF abnormalities, and findings on EEG and
neuroimaging, were indistinguishable from other patho-
gens. Hence, an accurate laboratory diagnosis of M. pneu-
moniae infection is vital. Although several reports showed
positive results in the detection of M. pneumoniae in CSF
specimens from patients with M. pneumoniae-associated
encephalopathy,5,7,8,13e16 in this study, technical diffi-
culties, the possible existence of inhibitors,17 an unfavor-
able environment for M. pneumoniae growth in CSF,
antibiotic treatment prior to the collection of specimens,18
immune responses, and other undetermined factors might
explain the negative results of PCR in the CSF in our cases
and others.19 Importantly, a negative result of M. pneu-
moniae DNA in the CSF cannot exonerate the involvement
of M. pneumoniae in CNS. M. pneumoniae culture is not
recommended for the diagnosis of acute M. pneumoniae
infection, because M. pneumoniae requires special mediaFigure 1. Correlation between the level of immunoglobulin
M and intervals between respiratory illness and onset of
neurological symptoms. >, patients with good outcome; -,
patients with poor outcome. BU/mL Z binding units per
milliliter serum; IgMZ immunoglobulin M. The vertical broken
line is the cutoff date of the intervals between respiratory
illness and onset of neurological symptoms between groups
with good outcomes and poor outcomes; the horizontal broken
line is the cutoff IgM concentration between groups with good
outcomes and poor outcomes.and needs weeks to grow.20 The diagnosis can also be made
by serologic tests for IgM and IgG antibodies to M. pneu-
moniae in paired (acute- and convalescent-phase) serum
samples. For the IgG study, it may take at least 3 weeks for
the significant rise of IgG titers in the acute infection.21 For
the IgM study, it is fast and convenient and the changes of
titers are fairly consistent in childhood during the acute
phase.8,22 For these reasons, the M. pneumoniae IgM test is
commonly used in the screening of pediatric patients with
suspicious M. pneumoniae infection.
Because the etiology of the encephalopathy was initially
unclear, we performed a wide range of bacteriological and
viral tests. Apart from a positive M. pneumoniae IgM, most
of the tests were negative. Whether M. pneumoniae is
playing a role as the main cause or a “bystander” and/or a
“mixed infection” remains unclear.23 It has been recently
reported that co-infection of M. pneumoniae with other
bacterial and/or viral pathogens is not rare.24,25 We cannot
exclude the possibility that some children might have co-
infection with other bacterial or viral pathogens, such as
Japanese encephalitis (JE) virus, West Nile virus, or Hen-
dra/Nipah virus, which are more virulent than M. pneu-
moniae. Additionally, several viral antigens may cross-react
with the M. pneumoniae IgM assay and cause false-posi-
tives. As such, the clinical implications of mixed infections,
compared with a sole agent, remain unresolved. These are
the limitations of this study.
The incidence of M. pneumoniae-associated encepha-
lopathy in this study was 1.1%, which is consistent with data
from previous studies.26 More than half of the patients (6/
11) in this study showed neurological sequelae after 6
months or more follow-up. Because little evidence sup-
ported macrolides and immunomodulatory agents, such as
corticosteroids and IVIG, for M. pneumoniae associated
encephalopathy, it would be useful to have some parame-
ters to predict their outcomes. As some clinical charac-
teristics of M. pneumoniae are similar to those observed in
systemic viral infections, the titers of M. pneumoniae IgM,
like the titers of Cytomegalovirus, might link to patients’
outcomes27. Additionally, the intervals between respiratory
and CNS manifestations were proposed to be related to the
mechanisms and outcomes of patients with M. pneumoniae
associated encephalopathy.15 However, we think that each
of them is too simplified and shallow in the understanding
of this disease. A combination of these two viewpoints in
our cases led to an important conclusion, that is, higher
M. pneumoniae IgM titers and longer intervals between
respiratory and CNS manifestations are associated with
worse outcomes. We postulated that in patients with
relatively low concentrations of IgM titers (<51.3 BU/mL)
and shorter intervals (<9.5 days), the IgM, which was
induced/activated by M. pneumoniae or other
unidentified pathogens, might not cause too many
dysregulated immune cascades and less tissue damage
and sequelae. However, if the intervals were too long and
the titers of IgM were too high, the consequences of
induced/activated direct and/or indirect immune attacks
might end in a poor prognosis. These findings suggest that
IgM titers and the intervals between respiratory illness
and onset of neurological symptoms may be associated
with a worse outcome in patients with M. pneumoniae
encephalopathy.
502 C.-F. Hu et al.In conclusion, patients with M. pneumoniae-associated
encephalopathy may show a wide array of manifestations.
A negative result of M. pneumoniae DNA in the CSF cannot
exonerate the involvement of M. pneumoniae in the CNS
diseases. A combination of the intervals between respira-
tory illness and onset of neurological symptoms and serum
IgM titer may connect to patients’ outcomes.Conflicts of interest
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